Can a gene test spare breast cancer patients from extra radiation?

NCT ID NCT04517266

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial is testing whether a genomic test can identify early-stage breast cancer patients who might safely skip radiation to the internal mammary lymph nodes. Participants have 1-3 positive lymph nodes and are considered at intermediate risk. Half will receive standard radiation to the chest and supraclavicular area, while the other half will also receive internal mammary irradiation. The goal is to see if skipping this extra radiation does not increase the risk of cancer returning within two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Radiation therapy (internal mammary irradiation vs. omission)
What this could lead to
If successful, this could personalize breast cancer treatment, sparing some women from unnecessary radiation and its side effects.
What could go wrong
The trial is relatively small and early, and the long-term benefits of skipping this radiation are uncertain. There is a risk of increased cancer recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ruijin Hospital, Shanghai jiaotong univestigy school of medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.